News
A new addition to our NGAL portfolio: Anti-NGAL (mouse) antibody pair
August 18 2008
Rat NGAL ELISA launched
June 27 2008
AACC 2008 Annual Meeting, 27-31 July 2008, Washington DC,
June 09 2008
INTERLEC-23 11-16 July 2008, Scotland
June 04 2008
An important addition to our complement antibody collection: Anti-C5b-9 (human) antibody
May 27 2008
New tools for cancer research: Plasminogen Activation System anti-bodies
May 05 2008
Product launch - Anti-NGAL (monkey) antibody
April 10 2008
The Biomarker World Congress 2008, 19-21 May - Philadelphia, USA
April 10 2008
ISICEM, Brussels, Belgium 18-21 March 2008
March 04 2008
BioPorto at ToxExpo, Seattle, Washington 16-20 March 2008
February 13 2008
An important addition to our complement antibody collection: Anti-C5b-9 (human) antibody
May 27 2008 by Lisbeth Kobberup Milling
BioPorto Diagnostics is happy to be able to offer a new monoclonal antibody DIA 011-01, which enables the measurement of the terminal complement complex (TCC), which is formed in the terminal step of the complement cascade.
C5b-9 is also known as the TCC. The TCC consists of C5b, C6, C7, C8 and C9 and forms transmembrane channels which displace lipid molecules and other constituents, thus disrupting the phospholipid bilayer of target cells leading to cell lysis by osmotic leakage. The complex contains neoantigens that are absent from the individual native components and the new monoclonal antibody DIA 011-01 is directed against a neoepitope exposed in C9 when incorporated into TCC.
By launching DIA 011-01 BioPorto Diagnostics now offers a comprehensive collection of complement antibodies for research use.
